Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$31.23
+2.9%
$29.22
$23.23
$42.29
$1.00B0.64398,763 shs258,092 shs
Dova Pharmaceuticals Inc stock logo
DOVA
Dova Pharmaceuticals
$28.04
$28.04
$5.62
$28.54
$807.55M2.74499,313 shs35,036 shs
Eagle Pharmaceuticals, Inc. stock logo
EGRX
Eagle Pharmaceuticals
$3.00
+3.6%
$2.21
$1.50
$3.00
$38.96M0.838,193 shs620 shs
Provention Bio, Inc. stock logo
PRVB
Provention Bio
$24.98
$24.58
$3.18
$25.00
$2.37B2.472.28 million shs218,200 shs
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
$5.02
+0.9%
$4.45
$3.81
$6.37
$295.53M0.68603,067 shs163,427 shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
0.00%+1.47%+0.56%+10.92%-5.62%
Dova Pharmaceuticals Inc stock logo
DOVA
Dova Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Eagle Pharmaceuticals, Inc. stock logo
EGRX
Eagle Pharmaceuticals
0.00%+3.45%+33.33%+62.16%-45.45%
Provention Bio, Inc. stock logo
PRVB
Provention Bio
0.00%0.00%0.00%0.00%0.00%
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
0.00%+4.48%+8.33%+19.19%-4.69%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
4.2667 of 5 stars
3.41.00.03.03.10.82.5
Dova Pharmaceuticals Inc stock logo
DOVA
Dova Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Eagle Pharmaceuticals, Inc. stock logo
EGRX
Eagle Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Provention Bio, Inc. stock logo
PRVB
Provention Bio
N/AN/AN/AN/AN/AN/AN/AN/A
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
4.3952 of 5 stars
3.82.00.04.20.63.31.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
2.75
Moderate Buy$43.7540.09% Upside
Dova Pharmaceuticals Inc stock logo
DOVA
Dova Pharmaceuticals
0.00
N/AN/AN/A
Eagle Pharmaceuticals, Inc. stock logo
EGRX
Eagle Pharmaceuticals
0.00
N/AN/AN/A
Provention Bio, Inc. stock logo
PRVB
Provention Bio
0.00
N/AN/AN/A
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
3.50
Strong Buy$16.50229.01% Upside

Current Analyst Ratings Breakdown

Latest VNDA, DOVA, EGRX, PRVB, and COLL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/14/2025
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight$13.00
5/13/2025
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/9/2025
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$36.00 ➝ $37.00
5/7/2025
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00 ➝ $20.00
4/9/2025
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$46.00 ➝ $46.00
(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$631.45M1.59$12.70 per share2.46$7.10 per share4.40
Dova Pharmaceuticals Inc stock logo
DOVA
Dova Pharmaceuticals
$10.35M78.02N/AN/A$2.71 per share10.35
Eagle Pharmaceuticals, Inc. stock logo
EGRX
Eagle Pharmaceuticals
$257.55M0.15$7.50 per share0.40N/A
Provention Bio, Inc. stock logo
PRVB
Provention Bio
$12.90M183.54N/AN/A$1.40 per share17.84
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
$198.77M1.49N/AN/A$9.24 per share0.54
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$69.19M$1.2225.605.19N/A6.61%99.08%15.14%8/6/2025 (Estimated)
Dova Pharmaceuticals Inc stock logo
DOVA
Dova Pharmaceuticals
-$72.28M-$2.60N/AN/AN/A-544.09%-101.60%-67.21%N/A
Eagle Pharmaceuticals, Inc. stock logo
EGRX
Eagle Pharmaceuticals
$35.64MN/A0.00N/AN/AN/AN/AN/A
Provention Bio, Inc. stock logo
PRVB
Provention Bio
-$113.57M-$1.53N/AN/AN/A-880.69%-103.36%-69.08%N/A
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
-$18.90M-$0.75N/AN/AN/A-21.98%-8.30%-6.85%7/30/2025 (Estimated)

Latest VNDA, DOVA, EGRX, PRVB, and COLL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/30/2025Q2 2025
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
-$0.34N/AN/AN/A$54.77 millionN/A
5/8/2025Q1 2025
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$1.50$1.49-$0.01$0.07$174.96 million$177.76 million
5/7/2025Q1 2025
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
-$0.55-$0.50+$0.05-$0.50$45.13 million$50.04 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
N/AN/AN/AN/AN/A
Dova Pharmaceuticals Inc stock logo
DOVA
Dova Pharmaceuticals
N/AN/AN/AN/AN/A
Eagle Pharmaceuticals, Inc. stock logo
EGRX
Eagle Pharmaceuticals
N/AN/AN/AN/AN/A
Provention Bio, Inc. stock logo
PRVB
Provention Bio
N/AN/AN/AN/AN/A
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
3.30
1.08
1.01
Dova Pharmaceuticals Inc stock logo
DOVA
Dova Pharmaceuticals
0.41
5.64
5.37
Eagle Pharmaceuticals, Inc. stock logo
EGRX
Eagle Pharmaceuticals
N/AN/AN/A
Provention Bio, Inc. stock logo
PRVB
Provention Bio
0.19
1.93
1.92
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
N/A
3.93
3.91
CompanyEmployeesShares OutstandingFree FloatOptionable
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
21032.13 million31.33 millionOptionable
Dova Pharmaceuticals Inc stock logo
DOVA
Dova Pharmaceuticals
11528.80 millionN/AOptionable
Eagle Pharmaceuticals, Inc. stock logo
EGRX
Eagle Pharmaceuticals
10012.99 million9.23 millionNo Data
Provention Bio, Inc. stock logo
PRVB
Provention Bio
8294.78 million82.37 millionNot Optionable
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
29058.93 million53.69 millionOptionable

Recent News About These Companies

VNDA - Vanda Pharmaceuticals Inc Chart - Morningstar
Brokers Issue Forecasts for VNDA FY2026 Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

Collegium Pharmaceutical stock logo

Collegium Pharmaceutical NASDAQ:COLL

$31.23 +0.88 (+2.90%)
As of 01:15 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Dova Pharmaceuticals stock logo

Dova Pharmaceuticals NASDAQ:DOVA

Dova Pharmaceuticals, Inc., a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead product candidate is DOPTELET that is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease scheduled to undergo a procedure. It also develops DOPTELET for the treatment of chronic immune thrombocytopenia and chemotherapy-induced thrombocytopenia. Dova Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Durham, North Carolina.

Eagle Pharmaceuticals stock logo

Eagle Pharmaceuticals NASDAQ:EGRX

$3.00 +0.11 (+3.63%)
As of 07/3/2025 09:30 AM Eastern

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.

Provention Bio stock logo

Provention Bio NASDAQ:PRVB

Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohn's disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Red Bank, NJ.

Vanda Pharmaceuticals stock logo

Vanda Pharmaceuticals NASDAQ:VNDA

$5.01 +0.05 (+0.91%)
As of 01:14 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.